NeuroBo Pharmaceuticals, Inc. (NRBO)
NASDAQ: NRBO · Real-Time Price · USD
2.860
+0.010 (0.35%)
Oct 29, 2024, 4:00 PM EDT - Market closed
NeuroBo Pharmaceuticals Employees
NeuroBo Pharmaceuticals had 8 employees as of December 31, 2023. The number of employees increased by 6 or 300.00% compared to the previous year.
Employees
8
Change (1Y)
6
Growth (1Y)
300.00%
Revenue / Employee
n/a
Profits / Employee
-$3,237,375
Market Cap
24.27M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8 | 6 | 300.00% |
Dec 31, 2022 | 2 | -3 | -60.00% |
Dec 31, 2021 | 5 | -2 | -28.57% |
Dec 31, 2020 | 7 | -5 | -41.67% |
Dec 31, 2019 | 12 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Pluri | 118 |
Tonix Pharmaceuticals Holding | 103 |
PolyPid | 62 |
Spruce Biosciences | 29 |
Cognition Therapeutics | 28 |
BioVie | 14 |
Nexalin Technology | 6 |
Cadrenal Therapeutics | 4 |
NRBO News
- 4 weeks ago - NeuroBo Pharmaceuticals to Participate in Investor Conferences in October - PRNewsWire
- 4 weeks ago - NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity - PRNewsWire
- 2 months ago - NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - PRNewsWire
- 2 months ago - NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity - PRNewsWire
- 3 months ago - NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity - PRNewsWire
- 3 months ago - NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 - PRNewsWire
- 3 months ago - NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July - PRNewsWire